Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

References

• CannonMJonesPNeuroepidemiology: schizophreniaJ Neurol Neurosurg Psychiatry1996616046138648325
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders4th ed, Text RevisionWashington DCAmerican Psychiatric Association2000
   Google Scholar
• McGlashanTHA Selective Review of Recent North American Long- Term Follow up Studies of SchizophreniaSchizophr Bull19881445155423064280
   PubMed Web of Science ®Google Scholar
• RiceDPKelmanSMillerLSThe economic burden of mental illnessHosp Community Psychiatry199243122712321459546
   PubMedGoogle Scholar
• JohnstoneECSchizophrenia: problems in clinical practiceLancet19933415365388094782
   PubMed Web of Science ®Google Scholar
• DolderCRLacroJPDunnLBAntipsychotic medication adherence: is there a difference between typical and atypical agents? [published correction appears in Am J Psychiatry. 2002;159:514]Am J Psychiatry200215910310811772697
   PubMed Web of Science ®Google Scholar
• DavisJMetalonLWatanabeMDepot antipsychotic drugs. Place in therapyDrugs1994477417737520856
   PubMed Web of Science ®Google Scholar
• KeithSJKaneJMPartial compliance and patient consequences in schizophrenia: our patients can do betterJ Clin Psychiatry200364111308131514658944
   PubMed Web of Science ®Google Scholar
• LeuchtSHeresSEpidemiology, clinical consequences, and psychosocial treatment of non-adherence in schizophreniaJ Clin Psychiatry200667Suppl 53816822090
   PubMed Web of Science ®Google Scholar
• FalloonIRHHeldTRonconeROptimal treatment strategies to enhance recovery from schizophreniaAust NZ J Psychiatry19983214349
   PubMed Web of Science ®Google Scholar
• RichelsonESouderTBinding of antipsychotic drugs to human brain receptors. Focus on newer generation compoundsLife Sci200068293911132243
   PubMed Web of Science ®Google Scholar
• MeltzerHYMatsubaraSLeeJCClassification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi valuesJ Pharmacol Exp Ther19892512382462571717
   PubMed Web of Science ®Google Scholar
• MeltzerHYWhat’s atypical about atypical antipsychotic drugs?Curr Opin Pharmacol200441535715018839
   PubMed Web of Science ®Google Scholar
• FleischhakerWWSecond generation antipsychotic long-acting injections: systematic reviewBr J Psychiatry20091952936
   Web of Science ®Google Scholar
• American Psychiatric AssociationPractice Guideline for the Treatment of Patients with Schizophrenia2nd edArlington (VA)American Psychiatric Association2004
   Google Scholar
• RichelsonEReceptor pharmacology of neuroleptics: relation to clinical effectsJ Clin Psychiatry1999601051410340682
   PubMed Web of Science ®Google Scholar
• BymasterFPFalconeJFBauzonDPotent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapineEur J Pharmacol200143023341349
   Web of Science ®Google Scholar
• ZengXPLeFRichelsonEMuscarinic m4 receptor activation by some atypical antipsychotic drugsEur J Pharmacol199732133493549085047
   PubMed Web of Science ®Google Scholar
• BymasterFPRasmussenKCalligaroDOIn vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drugJ Clin Psychiatry199758Suppl 1028369265914
   PubMed Web of Science ®Google Scholar
• BymasterFPCalligaroDOFalconeJFRadioreceptor binding profile of the atypical antipsychotic olanzapineNeuropsychopharmacology199614287968822531
   PubMed Web of Science ®Google Scholar
• FuYZhuZTChenLJYuLPJinGZBehavioral characteristics of olanzapine: an atypical neurolepticActa Pharmacol Sin200021432933411324461
   PubMed Web of Science ®Google Scholar
• NinanIJardemarkKEWangRYDifferential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortexSynapse 2003482667912619040
   PubMed Web of Science ®Google Scholar
• FumagalliFMolteniRRoceriMEffect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activityJ Neurosci Res200372562262812749027
   PubMed Web of Science ®Google Scholar
• ParikhVKhanMMMahadikSPOlanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidolNeurosci Lett2004356213513914746882
   PubMed Web of Science ®Google Scholar
• YoshimuraRShinkaiKToyohiraYEffects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cellsHum Psychopharmacol20052047748416158449
   PubMed Web of Science ®Google Scholar
• HoriHYoshimuraRYamadaYEffects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patientsInt Clin Psychopharmacol200722212717159456
   PubMed Web of Science ®Google Scholar
• TaylorDMMcAskillRAtypical antipsychotics and weight gain – a systematic reviewActa Psychiatr Scand200010141643110868465
   PubMed Web of Science ®Google Scholar
• WetterlingTBodyweight gain with atypical antipsychotics: a comparative reviewDrug Saf2001241597411219487
   PubMed Web of Science ®Google Scholar
• PatelJKBuckleyPFWoolsonSMetabolic profiles of second- generation antipsychotics in early psychosis: findings from the CAFE studySchizophr Res20091111391619409756
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyZypadhera (TM) 300 mg technical detailsEuropean Commission20091221
   Google Scholar
• MelkerssonKClozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitroEur Neuropsychopharmacol200414211511915013026
   PubMed Web of Science ®Google Scholar
• MelkerssonKKhanAHildingAHultingALDifferent effects of antipsychotic drugs on insulin release in vitroEur Neuropsychopharmacol200111532733211597818
   PubMed Web of Science ®Google Scholar
• WuRRZhaoJPLiuZNEffects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophreniaPsychopharmacology 2006186457257816601995
   PubMed Web of Science ®Google Scholar
• SaddichhaSManjunathaNAmeenSAkhtarSMetabolic syndrome in first episode schizophrenia – a randomized double-blind controlled, short-term prospective studySchizophr Res20081011326627218282690
   PubMed Web of Science ®Google Scholar
• EselETuranMTSofougluSImprovement of tardive dyskinesia in a bipolar patient with olanzapineEur Psychiatry20001543843911112937
   PubMed Web of Science ®Google Scholar
• CaseyDESide effect profiles of new antipsychotic agentsJ Clin Psychiatry1996571140458941170
   PubMed Web of Science ®Google Scholar
• BouchardRHDemersMFSimoneauIAtypical antipsychotics and cardiovascular risk in schizophrenic patientsJ Clin Psychopharmacol200121111011111199934
   PubMed Web of Science ®Google Scholar
• DriciMDWangWXLiuXKWoosleyRLFlockhartDAProlongation of QT interval in isolated feline hearts by antipsychotic drugsJ Clin Psychopharmacol19981864774819864081
   PubMed Web of Science ®Google Scholar
• MorissettePHreicheRMalletLVoDKnausEETurgeonJOlanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium currentJ Psychopharmacol200721773574117092964
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyZypadhera (TM) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) for Maintenance Treatment of SchizophreniaCNW Group2008
   Google Scholar
• DavisJMChenNChoice of Maintenance Medication for SchizophreniaJ Clin Psychiatry200364Suppl 16243314680416
   PubMed Web of Science ®Google Scholar
• LiebermanJAMcEvoyJPSwartzMSEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• KahnRSFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet20083711085109718374841
   PubMed Web of Science ®Google Scholar
• BeasleyCMJrStaufferVLLiu-SeifertHAll-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysisJ Clin Psychopharmacol200727325225817502771
   PubMed Web of Science ®Google Scholar
• GulliverADetkeHCMcDonnellDPBergstromRFLinDOlanzapine long-acting injection: pharmacokinetic and dose correspondence data relative to oral olanzapine [poster]Int J Neuropsychopharmacol200811Suppl 1152153
   Google Scholar
• KapurSZipurskyRBRemingtonG5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigationAm J Psychiatry199815579219289659858
   PubMed Web of Science ®Google Scholar
• MamoDKapurSKeshavanMD2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophreniaNeuropsychopharmacology20083329830417443131
   PubMed Web of Science ®Google Scholar
• LaurielloJLambertTAndersenSLinDTaylorCCMcDonnellDAn 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophreniaJ Clin Psychiatry200869579079918452346
   PubMed Web of Science ®Google Scholar
• KaneJMDetkeHCNaberDOlanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophreniaAm J Psychiatry 2010167218118920008947
   PubMed Web of Science ®Google Scholar
• BisharaDTaylorDUpcoming Agents for the Treatment of Schizophrenia Mechanism of Action, Efficacy and TolerabilityDrugs200868162269229218973393
   PubMed Web of Science ®Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT00320489?term=olanzapine+pamoate&rank=1
   Google Scholar
• GodfreyJLDetkeHCMontgomeryWSZhaoFMcDonnellDQuality of life and patient-reported outcomes: comparisons of individuals with schizophrenia treated with oral and long-acting injectable formulations of olanzapine [poster]Value in Health20091217A363
   Google Scholar
• KaragianisJMcDonnellDAndersenSDetkeHWatsonS160-week interim results from an open-label extension trial of olanzapine longacting injectionPoster (PO1.27) presented at: WPA International Congress2009 Apr 1–4Florence, Italy
   Google Scholar
• www.fda.gov/ohrms/dockets/ac/08/slides/2008-4338s1-01-FDAZhang.ppt – 2008-03-17.
   Google Scholar
• McDonnellDSorsaburuSBrunnerEPost-injection delirium/sedation syndrome observed with olanzapine long-acting injection: review of the first 25 eventsEur Neuropsychopharm2008184S437S438
   Web of Science ®Google Scholar
• GulliverAMcDonnellDPSorsaburuSInjection-related adverse events observed with olanzapine long-acting injection [poster]Int J Neuropsychopharmacol200811Suppl 1152
   Google Scholar
• CitromeLOlanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second generation antipsychoticInt J Clin Pract200963114015018834452
   PubMed Web of Science ®Google Scholar
• McEvoyJPRisks versus benefit of different types of long-acting injectable antipsychoticsJ Clin Psychiatry200667Suppl 5151816822092
   PubMed Web of Science ®Google Scholar
• JarskogLFGlantzLAGilmoreJHLiebermanJAApoptotic mechanisms in the pathophysiology of schizophreniaProg Neuro Psychopharmacol Biol Psychiatry200529846858
   PubMed Web of Science ®Google Scholar
• KaneJMReview of treatments that can ameliorate nonadherence in patients with schizophreniaJ Clin Psychiatry200667S591416822091
   PubMed Web of Science ®Google Scholar
• HeresSHamannJKisslingWLeuchtSAttitudes of psychiatrists toward antipsychotic depot medicationJ Clin Psychiatry200667121948195317194274
   PubMed Web of Science ®Google Scholar
• von Hausswolff-JuhlinYBjartveitMLindströmEJonesPSchizophrenia and physical health problemsActa Psych Scand20091194381521
   Web of Science ®Google Scholar
• MeyerJMStahlSMThe metabolic syndrome and schizophreniaActa Psych Scand2009119414
   PubMed Web of Science ®Google Scholar
• OsbornDPJLevyGNazarethIPetersenIIslamAKingMBRelative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s general practice research databaseArch Gen Psychiatry20076424224917283292
   PubMed Web of Science ®Google Scholar